The PALLAS (NCT02513394) is a randomized phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR-positive, HER2-negative early breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.